Mouse protection assay for group B streptococcus type III

Area of Science:

• Microbiology
• Immunology
• Infectious Diseases

Background:

• Group B Streptococcus (GBS) type III is a significant pathogen.
• Assessing protective immunity against GBS is crucial for developing effective vaccines and treatments.
• Existing methods for evaluating antibody protection can be further refined.

Purpose of the Study:

• To evaluate the efficacy of a murine-mucin model for assaying protective antibodies against GBS type III.
• To determine the protective capacity of hyperimmune rabbit sera and human sera in this model.
• To explore the potential of the model for screening antibody levels in vaccine development and passive immunization.

Main Methods:

• Utilized a mucin model in mice to challenge with GBS type III strains.
• Prepared hyperimmune rabbit sera against reference and clinical GBS type III isolates.
• Tested normal rabbit sera, heterologous antisera, pooled human gamma globulin, and sera from vaccinated adults.

Main Results:

• Hyperimmune rabbit sera demonstrated significant protection against lethal GBS type III challenge.
• Absorption studies confirmed the specificity of the protective antibodies.
• Pooled human gamma globulin provided protection, while adult human sera showed variable effects, enhancing lethality with one isolate.
• Sera from vaccinated adults were also assessed for protective antibody levels.

Conclusions:

• The murine-mucin-GBS model is a viable tool for measuring protective antibody levels against GBS type III.
• This model can be used to screen antibody responses post-vaccination.
• The model holds potential for evaluating antibody efficacy in pooled human gamma globulin for passive immunization of high-risk individuals.